Global Generic Oncology Drug Market Catalysed by Increasing Number of Cancer Patients

The global generic oncology drug market has experienced a significant growth in recent years. The primary factor influencing the demand for generic oncology drugs is rise in the population of cancer patients. As a result of this, several healthcare organisations are encouraging the use of these drugs.



The latest report by IMARC Group titled, “Generic Oncology Drug Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023”, finds that the global generic oncology drug market reached a value of more than US$ 20.4 Billion in 2017, growing at a CAGR of around 12% during 2010-2017. Generic drugs account for almost 80% of the total prescriptions across different medical specialties. After branded drugs go off-patent, manufacturers in the pharmaceuticals industry secure the right to develop and sell a generic version of those drugs. Generic drugs carry the same functional properties as their branded counterparts. Additionally, these are available in the market at a much cheaper price; almost one-tenth of the branded drug. Currently, there is a high demand for generic oncology drugs as a result of a growth in the number of cancer patients across the globe. Some of most commonly diagnosed cancers around the world include lung, breast, and colorectum cancers.

Global Generic Oncology Drug Market

Highlights of the global generic oncology drug market:

  • The market is driven by the patent expiry of several blockbuster drugs
  • The market is expected to reach a value of US$ 36.7 Billion by 2023.
  • Cost containment measures from the government and healthcare authorities are also expected to drive this market.

According to a research, in 2017 around 15 Million patients were diagnosed with cancer, among which more than 8 Million lost their lives to it. The major causes of the dissemination of cancer on such a wide scale are lack of awareness and high costs of treatment. Most patients, particularly in the developing regions, do not have access to expensive drugs and therapies that are required to cure cancer. Due to this, manufacturing of generic oncology drugs is promoted by both, government and non-government health organisations in order to provide treatment to the maximum number of people at affordable rate. Further, the market is expected to reach a value of US$ 36.7 Billion by 2023.


About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal